Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202) Meeting Abstract
| Authors: | Barlesi, F.; Felip, E.; Popat, S.; Solomon, B. J.; Wolf, J.; Li, B. T.; Wu, Y. L.; Kerr, K.; Akamatsu, H.; Camidge, D. R.; Gupta, R. G.; Meloni, A.; Dai, T.; Borghaei, H. |
| Abstract Title: | Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202) |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557406378 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.TPS8653 |
| Notes: | Meeting Abstract: TPS8653 -- Source: Wos |
